CN108324874A - Treat syndrome of intermingled heat and cold urarthritis on behalf of the tea - Google Patents

Treat syndrome of intermingled heat and cold urarthritis on behalf of the tea Download PDF

Info

Publication number
CN108324874A
CN108324874A CN201810432209.3A CN201810432209A CN108324874A CN 108324874 A CN108324874 A CN 108324874A CN 201810432209 A CN201810432209 A CN 201810432209A CN 108324874 A CN108324874 A CN 108324874A
Authority
CN
China
Prior art keywords
group
urarthritis
cold
heat
intermingled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810432209.3A
Other languages
Chinese (zh)
Other versions
CN108324874B (en
Inventor
张琳
肖楠
薛崇祥
罗楠
郭文晖
付勇芳
张晓楠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Medical University
Original Assignee
Dalian Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Medical University filed Critical Dalian Medical University
Priority to CN201810432209.3A priority Critical patent/CN108324874B/en
Publication of CN108324874A publication Critical patent/CN108324874A/en
Application granted granted Critical
Publication of CN108324874B publication Critical patent/CN108324874B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention, which discloses, a kind for the treatment of syndrome of intermingled heat and cold urarthritis on behalf of the tea, it is characterised in that each component mass ratio is as follows：2 parts of rose, 2 parts of Radix Angelicae Sinensis, 1 part of Poria cocos, 1 part of Semen Coicis, 1 part of pueraria lobata, 1 part of Radix Glycyrrhizae, 1 part of rde bean, 1 part of Chinese yam.Overcome traditional decoction and decoct the shortcomings of cumbersome, inconvenient to carry, can several times of drinking at any time for a long time, slowly recuperate under medical treatment, can not only alleviate syndrome of intermingled heat and cold but also can effectively treat urarthritis, and the recurrent exerbation of avoidable urarthritis.

Description

Treat syndrome of intermingled heat and cold urarthritis on behalf of the tea
Technical field
The present invention relates to one kind on behalf of the tea, especially a kind of to treat syndrome of intermingled heat and cold urarthritis on behalf of the tea.
Background technology
As living and diet level improves, dietary structure variation causes human body health hidden danger occur.Hyperuricemia and Patient with gout incidence is in apparent ascendant trend, and general population's prevalence of gout about 1 ~ 3%, male to female ratio is about 15：1, average year Age is 48.28 years old.Clinically, urarthritis is treated using non-steroid anti-inflammatory drug and glucocorticoid etc., Chang Yin Play the side effects such as gastrointestinal toxicity, dependence, liver and bone marrow toxicity, allergy and Toxicity of Kidney.To avoid Western medicine from causing Side effect, existing traditional Chinese medicine is applied to the treatment of urarthritis at present, but offer limited effectiveness.Chinese medicine is to use on behalf of the tea The Chinese medicine of medicine-food two-purpose or with tealeaves adapted, it is the same to brew or decoct after image tea, safe, can several times of drinking at any time for a long time. But there is no be suitble to syndrome of intermingled heat and cold so far（Sympotoms caused by cold factors are interlocked with heat symptom-complex, sympotoms caused by cold factors：Limb cold curl up sleeping, clear abundant urine, stool It is dilute half congealed etc.；Heat symptom-complex：Body heat is irritated, appearance it is red it is red, lip is red and dry, the dry thirsty, cool drink of pharynx, constipation, scanty drak urine and tongue Red yellow tongue fur etc.）Patient drinks, and can alleviate syndrome of intermingled heat and cold and can effectively treat urarthritis on behalf of the tea.
Invention content
The present invention be in order to solve the above-mentioned technical problem present in the prior art, provide it is a kind of treat syndrome of intermingled heat and cold pain Wind is arthritic on behalf of the tea.
Technical solution of the invention is：It is a kind of to treat syndrome of intermingled heat and cold urarthritis on behalf of the tea, feature It is that each component mass ratio is as follows：2 parts of rose, 2 parts of Radix Angelicae Sinensis, 1 part of Poria cocos, 1 part of Semen Coicis, 1 part of pueraria lobata, 1 part of Radix Glycyrrhizae, rde bean 1 part, 1 part of Chinese yam.
The present invention overcomes traditional decoctions to decoct the shortcomings of cumbersome, inconvenient to carry, can several times of drinking at any time for a long time, slowly adjust It controls, can not only alleviate syndrome of intermingled heat and cold but also can effectively treat urarthritis, and can avoid the hair repeatedly of urarthritis Make.
Specific implementation mode
On behalf of the tea, each component mass ratio is as follows for the cold card urarthritis for the treatment of of the present invention：20g parts of rose, when Return 20g, Poria cocos 10g, Semen Coicis 10g, pueraria lobata 10g, Radix Glycyrrhizae 10g, rde bean 10g, Chinese yam 10g.By the above integration of drinking and medicinal herbs It is crushed after mixing after Chinese medicine individually crushes, or mixing, tea bag then is made in gained crushed material packaging（5g/ packets or 10g/ packets） , brew or taken after decocting.
Experiment：
By 20g parts of rose, Radix Angelicae Sinensis 20g, Poria cocos 10g, Semen Coicis 10g, pueraria lobata 10g, Radix Glycyrrhizae 10g, rde bean 10g and Chinese yam 10g is placed in round-bottomed flask, and 7 times of amount distilled waters, heating and refluxing extraction 2 times is added 2 hours every time, to merge extracting solution, steamed in rotation Extracting solution is concentrated into 100ml by hair instrument（Extracting solution of the embodiment of the present invention）, amount to 10 parts.
Semen Coicis, rde bean, Poria cocos, pueraria lobata and each 100g of Radix Angelicae Sinensis is taken to prepare folk prescription extracting solution respectively, extracting method is same as above, often Folk prescription extracting solution 100ml amounts to 10 parts.
1. grouping
72 200 ± 20g SD rats adaptable feds 3 days, are randomly divided into 9 groups, blank group, model group, positive drug group, this hair Bright embodiment group, Semen Coicis group, rde bean group, Poria cocos group and when be grouped into, every group 8.
2. prepared by urarthritis model
The crystallization of 500mg Monosodium urates plus 2ml Tween 80s are taken, is settled to 20ml with physiological saline, 25mg/ml uric acid is made in heating stirring Sodium solution.In addition to normal group, remaining group 10% chloraldurate of rat（0.3ml/100g）After intraperitoneal anesthesia, in right ankle joint Interior injection uric acid sodium solution（25mg/ml）, capsular ligament offside of being subject to heaves, and establishes rat urarthritis model.
3. Chinese medicine heat is trembled with fear prepared by mixed model of a syndrome
Urarthritis rat model established above is placed in high temperature（37±2℃）Environment one hour, low temperature（0±2℃） Environment one hour, it is daily alternately primary, continue two weeks, causes hot mixed card urarthritis rat model of trembling with fear.
4. administration
Normal group and model group give the physiological saline of therapeutic dose after modeling；Positive drug group gives the autumn according to 1.5mg/kg Tazettine is configured with physiological saline, and daily gastric infusion is primary；Group of the embodiment of the present invention gives extracting solution of the embodiment of the present invention, Remaining each group gives folk prescription extracting solution respectively, and dosage is 1ml/100g；Each group successive administration 7 days.
5. detection method
Naked-eye observation each group mouse state and 0 after modeling, 24,48,72,96,120,144,8 time points such as 168h, with nothing The perimeter value of elastic cotton thread and four use stainless steel band table calliper each group Rat Right metapedes ankle-joints, calculates and records ankle-joint Perimeter increases percentage, calculation formula：Perimeter increase percentage=（Minute point joint Zhou Jing-initial Zhou Jing）/ initial Zhou Jing ×100%.In taking rat blood serum after the last administration, using enzyme-linked immunization to α-NAG, β-gal, SOD, UA, TNF-α in serum Content is detected, and specific detecting step, method are operated by kit specification.
6. statistical method
All data are calculated using SPSS16.0 softwares, measurement data mean ± standard deviation（）It indicates, p≤ 0.05 has statistical significance.
7. result
7.1 naked-eye observation results：After the administration of group of the embodiment of the present invention, rat aversion to cold, peripheral coldness, body is tired thermophilic sleeping, and when stool is soft When hard symptom be obviously improved.Illustrate, the cold mixed card of heat can be effectively relieved in the embodiment of the present invention.
7.2 ankle-joint perimeters increase percentage（%）Such as table 1-1, table 1-2, table 1-3.
Table 1-1
Table 1-2
Table 1-3
a-p<0.01, b-p<0.05, compared with normal； c-p<0.01, compared with model, d-p <0.05, compared with model；e-p<0.01, f-p<0.05, compared with colchicine.
Table 1-1, table 1-2, table 1-3 the result shows that：Each point in time, blank control group and the significant difference of model group, Illustrate modeling success.When for 24 hours, positive drug group and the significant difference of model group illustrate that colchicin has therapeutic effect. When 48h, embodiment（The embodiment of the present invention）There was no significant difference for group and the significant difference of model group and positive drug group.72h When, embodiment group does not have significant difference with the significant difference of model group and positive drug group.96h and after, embodiment group tool Have the tendency that alleviating urarthritis.Each point in time, rde bean group, Poria cocos group, pueraria lobata group, when be grouped into, Semen Coicis group and mould Type group is compared to statistically significant, statistically significant compared with positive drug group, blank group, prompt rde bean, Poria cocos, Pueraria lobota The use of root, Radix Angelicae Sinensis, Semen Coicis simple has the function of slight relief urarthritis, but ineffective.
α-NAG, β-gal, SOD, UA, TNF-α content detection result such as table 2 in 7.3 serum.
Table 2
Grouping α-NGA(ng/L） β-gal（pg/ml） SOD(ng/L) UA（μmol/L) TNF-α（ng/L）
Blank group 182.25±3.06c 88.05±1.93ce 157.5±4.04ce 242.13±3.83ce 280.50±3.30ce
Model group 220.88±9.33ae 118.25±5.09ae 110.03±4.00ae 294.66±9.24ae 305.50±8.49ae
Positive drug group 185.54±2.46c 92.30±2.56c 149.50±7.31c 254.00±5.95c 282.75±5.23c
Embodiment group 183.00±1.85c 88.17±3.36cf 156.5±4.28cf 240.63±4.37ce 277.75±4.71c
Rde bean group 202.38±8.28ace 103.25±5.73ace 129.75±4.71ace 273.13±5.38ace 291.63±3.62ace
Poria cocos group 202.78±6.34ace 102.04±4.51ace 123.78±5.00ace 272.28±6.57ace 296.42±5.73ace
Pueraria lobata group 203.13±4.02ace 97.63±4.81ace 124.06±4.57ace 271.78±6.84ace 292.88±4.88ace
Work as grouping 221.08±7.17ace 123.16±4.50ace 118.61±4.71ace 294.96±4.00ace 299.91±5.74ace
Semen Coicis group 201.20±7.19ace 104.03±4.19ace 127.94±4.51ace 274.90±4.07ace 294.03±6.03ace
a-p<0.01, b-p<0.05, compared with normal；c-p<0.01, d-p<0.05,
compared with model；e-p<0.01, f-p<0.05, compared with colchicine.
①：α NAG blank control groups have significant difference with model group（p<0.05）, illustrate modeling success, and can be used as The index of drug evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group does not have with blank control group Significant difference illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group are than significant difference, with sky There was no significant difference with positive drug group for white group, and it is horizontal to illustrate that the embodiment of the present invention can reduce α-NGA.
②：β-gal blank control groups have significant difference with model group（p<0.05）, illustrate modeling success, and can make For the index of drug evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group and blank control group There is no significant difference, illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group than significant difference, with There was no significant difference for blank group and positive drug group, and it is horizontal to illustrate that the embodiment of the present invention can reduce β-gal.
③：SOD blank control groups have significant difference with model group（p<0.05）, illustrate modeling success, and can be used as The index of drug evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group does not have with blank control group Significant difference illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group are than significant difference, with sky There was no significant difference with positive drug group for white group, illustrates the embodiment of the present invention] SOD levels can be increased.
④：UA blank control groups have significant difference with model group（p<0.05）, illustrate modeling success, and can be used as medicine The index of object evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group does not have with blank control group Significant difference illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group are than significant difference, with blank There was no significant difference with positive drug group for group, illustrates that the embodiment of the present invention can reduce UA levels.
⑤：TNF-α blank control group has significant difference with model group（p<0.05）, illustrate modeling success, and can make For the index of drug evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group and blank control group There is no significant difference, illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group than significant difference, with There was no significant difference for blank group and positive drug group, illustrates that this hair inventive embodiments can reduce TNF-α level.
⑥：From the point of view of each index, rde bean group, Poria cocos group, pueraria lobata group, when be grouped into, Semen Coicis group it is equal with model group compared with It is statistically significant, it is statistically significant compared with positive drug group, blank group, prompt rde bean, Poria cocos, pueraria lobata, Radix Angelicae Sinensis, Semen Coicis The use of simple has the function of slight relief urarthritis, but ineffective.
To sum up the result shows that：
The present invention can not only alleviate the cold mixed card of heat, and have the function for the treatment of urarthritis well, can improve pain Arthroncus caused by wind arthritis, inflammatory factor change, Antioxidative Factors change etc..

Claims (1)

1. a kind for the treatment of syndrome of intermingled heat and cold urarthritis on behalf of the tea, it is characterised in that each component mass ratio is as follows：Rose Spend 2 parts, 2 parts of Radix Angelicae Sinensis, 1 part of Poria cocos, 1 part of Semen Coicis, 1 part of pueraria lobata, 1 part of Radix Glycyrrhizae, 1 part of rde bean, 1 part of Chinese yam.
CN201810432209.3A 2018-05-08 2018-05-08 Tea substitute for treating gouty arthritis with syndrome of intermingled cold and heat Active CN108324874B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810432209.3A CN108324874B (en) 2018-05-08 2018-05-08 Tea substitute for treating gouty arthritis with syndrome of intermingled cold and heat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810432209.3A CN108324874B (en) 2018-05-08 2018-05-08 Tea substitute for treating gouty arthritis with syndrome of intermingled cold and heat

Publications (2)

Publication Number Publication Date
CN108324874A true CN108324874A (en) 2018-07-27
CN108324874B CN108324874B (en) 2021-01-05

Family

ID=62935001

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810432209.3A Active CN108324874B (en) 2018-05-08 2018-05-08 Tea substitute for treating gouty arthritis with syndrome of intermingled cold and heat

Country Status (1)

Country Link
CN (1) CN108324874B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113318201A (en) * 2021-06-15 2021-08-31 湖南琥茗生物科技有限公司 Health food for reducing uric acid and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101596295A (en) * 2009-07-03 2009-12-09 云南天秀植物科技开发有限公司 A kind of pharmaceutical composition and preparation technology thereof who is used for the treatment of gout
CN105267399A (en) * 2015-11-06 2016-01-27 宁波优美科新材料有限公司 Medicine for treating cold-heat jumble symptom of rheumatoid arthritis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101596295A (en) * 2009-07-03 2009-12-09 云南天秀植物科技开发有限公司 A kind of pharmaceutical composition and preparation technology thereof who is used for the treatment of gout
CN105267399A (en) * 2015-11-06 2016-01-27 宁波优美科新材料有限公司 Medicine for treating cold-heat jumble symptom of rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
臧俊岐等: "《膳食内调，穴位外治痛风》", 31 December 2015, 黑龙江科学技术出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113318201A (en) * 2021-06-15 2021-08-31 湖南琥茗生物科技有限公司 Health food for reducing uric acid and preparation method thereof

Also Published As

Publication number Publication date
CN108324874B (en) 2021-01-05

Similar Documents

Publication Publication Date Title
CN102861298A (en) Traditional Chinese medicine composition for treating chronic gastritis
CN108324874A (en) Treat syndrome of intermingled heat and cold urarthritis on behalf of the tea
CN103386089A (en) Chinese medicine composition for treating liver-stomach disharmony
CN108310275A (en) Treat heat symptom-complex urarthritis on behalf of the tea
CN103071060B (en) Traditional Chinese medicine preparation for treating ankylosing spondylitis
CN104001131A (en) Oral traditional Chinese medicine for preventing and treating stress ulcers
CN104189368A (en) Traditional Chinese medicinal composition for treating spleen and stomach diseases and preparation method thereof
CN101129584A (en) Chinese medicine preparation for treating post partum hypogalactia
CN104474445A (en) Traditional Chinese medicine preparation for treating pernicious vomiting disease
CN108355083A (en) The cold card urarthritis for the treatment of is on behalf of the tea
CN104958707A (en) Formula and production process of thyroid panacea
CN102406913A (en) Chinese medicinal composition for treating melancholia
CN100571750C (en) The urticarial Chinese medicine decoction of a kind of treatment
CN106266334A (en) A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application
CN106728640A (en) It is a kind of to treat the Chinese medicine composition that irregular menstruation promotes pregnancy
CN104547223A (en) Traditional Chinese medicine for treating phlegm-blood stasis syndrome type non-alcoholic fatty liver disease
CN104666911A (en) Medicine for treating urticaria and preparation method thereof
CN103638441A (en) Traditional Chinese medicinal composition for treating fatty liver with liver stagnation and spleen deficiency symptom
CN105031354A (en) Unio margarita capsule used for curing gastroduodenal ulcer and preparation method and application of Unio margarita capsule
CN105434533A (en) Traditional Chinese medicine composition for treating liver cancer
CN104906385A (en) Traditional Chinese medicine composition for treating diarrhoea
CN104758784A (en) Traditional Chinese medicine composition for treating chronic gastritis
CN102698075B (en) Health-care herb tea used after gynecological operation, and preparation method thereof
CN104001137A (en) Traditional Chinese medicine (TCM) composition for treating diarrhea
CN104042907A (en) Traditional Chinese medicine for treating senile cataract

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant